102 related articles for article (PubMed ID: 1475868)
1. [The intravesical chemotherapy of surface tumors of the bladder].
Matveev BP; Figurin KM; Romanov VA; Burnaz AO
Urol Nefrol (Mosk); 1992; (4-6):13-5. PubMed ID: 1475868
[TBL] [Abstract][Full Text] [Related]
2. [The effect of intravesical chemotherapy on superficial urinary bladder cancer].
Moriyama M; Kubota Y; Miura T; Shuin T; Noguchi S
Hinyokika Kiyo; 1983 Mar; 29(3):351-5. PubMed ID: 6203382
[TBL] [Abstract][Full Text] [Related]
3. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
Huncharek M; McGarry R; Kupelnick B
Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
[TBL] [Abstract][Full Text] [Related]
4. [Instillation chemotherapy with peplomycin in superficial bladder cancer: clinical study on the effects of the direct antitumor activity and of the prophylaxis of recurrence].
Sonoda T; Osafune M; Matsuda M; Usami M
Hinyokika Kiyo; 1988 Mar; 34(3):574-81. PubMed ID: 2455442
[TBL] [Abstract][Full Text] [Related]
5. [Can topical chemoprevention modify the rate of recurrence and progression of superficial bladder cancer?].
Egghart G; Steegmüller O; Wenderoth U; Hautmann R
Urologe A; 1988 May; 27(3):147-51. PubMed ID: 3136576
[TBL] [Abstract][Full Text] [Related]
6. Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer.
Maffezzini M; Simonato A; Zanon M; Raber M; Carmignani G
J Urol; 1996 Jan; 155(1):91-3. PubMed ID: 7490907
[TBL] [Abstract][Full Text] [Related]
7. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder.
Lamm DL; Riggs DR; Traynelis CL; Nseyo UO
J Urol; 1995 May; 153(5):1444-50. PubMed ID: 7714962
[TBL] [Abstract][Full Text] [Related]
8. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R
Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
[TBL] [Abstract][Full Text] [Related]
9. [Intravesical chemotherapy of superficial bladder tumors].
Matsumura Y
Gan To Kagaku Ryoho; 1989 Feb; 16(2):193-8. PubMed ID: 2645832
[TBL] [Abstract][Full Text] [Related]
10. [Intravesical therapy: Influence on superficial bladder cancer progression].
García Rodríguez J; Fernández Gómez JM; Escaf Barmadah S; Alvarez Múgica M; Rodríguez Robles L; Martín Benito JL; San Martín Blanco A; Regadera Sejas J
Arch Esp Urol; 2007; 60(1):31-5. PubMed ID: 17408169
[TBL] [Abstract][Full Text] [Related]
11. [Phase I study of amrubicin hydrochroride (SM-5887) for superficial bladder cancer in intravesical chemotherapy].
Ohmori H; Yamato T; Asahi T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):475-82. PubMed ID: 11329781
[TBL] [Abstract][Full Text] [Related]
12. [Medical treatment of urothelial tumors of the bladder].
Ferrière JP; Dionet C; Dauplat J; Boiteux JP; Plagne R; Giraud B
Ann Urol (Paris); 1988; 22(4):229-34. PubMed ID: 3056230
[TBL] [Abstract][Full Text] [Related]
13. Mitomycin-C and BCG in intravesical chemotherapy and immunotherapy of superficial bladder cancer. Finnbladder Research Group.
Rintala E; Jauhiainen K; Alfthan O
Prog Clin Biol Res; 1989; 310():271-4. PubMed ID: 2505270
[No Abstract] [Full Text] [Related]
14. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors.
Colombo R; Da Pozzo LF; Lev A; Salonia A; Rigatti P; Leib Z; Servadio C; Caldarera E; Pavone-Macaluso M
J Urol; 1998 Mar; 159(3):783-7. PubMed ID: 9474148
[TBL] [Abstract][Full Text] [Related]
15. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
Evans CP
Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
[No Abstract] [Full Text] [Related]
16. What matters - early start or duration of chemotherapy instillation regimens or patient characteristics?
Kaasinen E
Eur Urol; 2008 May; 53(5):882-5; discussion 885-6. PubMed ID: 18262339
[No Abstract] [Full Text] [Related]
17. [The incidence of bladder tumor recurrences after transurethral resection during combined treatment].
Matveev BP; Shipilov VI; Gotsadze DT; Abdushelishvili KO; Pirtskhalaishvili GG
Urol Nefrol (Mosk); 1990; (3):53-6. PubMed ID: 2396341
[TBL] [Abstract][Full Text] [Related]
18. [Long-term results of intravesical prevention of recurrence with mitomycin C and adriamycin in patients with superficial bladder cancer].
Schwaibold H; Klingenberger HJ; Huland H
Urologe A; 1994 Nov; 33(6):479-83. PubMed ID: 7817443
[TBL] [Abstract][Full Text] [Related]
19. [Our experience with combined intravesical instillation therapy of superficial bladder tumor using Aclacinomycin-A (ACM) and cytosine arabinoside (CA)].
Tsugaya M; Iwase Y; Sakagami H; Washida H
Hinyokika Kiyo; 1987 Aug; 33(8):1180-4. PubMed ID: 3480687
[TBL] [Abstract][Full Text] [Related]
20. Is immediate postoperative intravesical chemotherapy beneficial in non-muscle- invasive bladder cancer?
Ayres BE; Crew JP;
BJU Int; 2010 Feb; 105 Suppl 2():14-7. PubMed ID: 20089093
[No Abstract] [Full Text] [Related]
[Next] [New Search]
